Open-label, Single Arm, Safety and Tolerability Dose Escalation Study of VAL-083 in Patients With Recurrent Malignant Glioma

Trial Profile

Open-label, Single Arm, Safety and Tolerability Dose Escalation Study of VAL-083 in Patients With Recurrent Malignant Glioma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 Jan 2017

At a glance

  • Drugs Dianhydrogalactitol (Primary)
  • Indications Brain cancer; Glioblastoma; Glioma
  • Focus Adverse reactions
  • Sponsors Del Mar Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 06 Jun 2016 Status changed from active, no longer recruiting to completed, according to a DelMar Pharmaceuticals media release.
    • 06 Jun 2016 Results published in the DelMar Pharmaceuticals Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top